[Legionella pneumonia in patients treated with infliximab].
Therapy with tumour necrosis factor-alfa inhibitors is widely used in various inflammatory disorders, but adverse events from severe infections with intracellular pathogens may occur. We describe two cases of severe pulmonary legionellosis in patients treated with infliximab for Crohn's disease and psoriasis, respectively. We conclude that legionella infections are probably more frequent in patients receiving immunosuppressive therapy with tumour necrosis factor-alfa inhibitors than in the background population.
Vinter
Hanne
H
Infektionsmedicinsk Afdeling, Aalborg Sygehus Syd, DK-9000 Aalborg.
Nielsen
Henrik Ib
HI
D000893:Anti-Inflammatory Agents / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology; D003879:Dermatologic Agents / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D000069285:Infliximab; D016952:Legionella pneumophila / Q000302:isolation & purification; D007877:Legionnaires' Disease / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D000069285:Infliximab